BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a reduced risk of adverse reactions that may have held back its uptake in the ...

Cognition Therapeutics surges 35% after a positive FDA meeting for Alzheimer’s drug zervimesine. Read more here.

NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...

Eisai has scaled down its sales expectations for Alzheimer's disease drug Leqembi after sluggish sales growth in the first half of the current fiscal year.

A scan that can detect Alzheimer’s disease before memory loss begins is now available in the UAE for the first time. The amyloid PET scan, recently launched at Cleveland Clinic Abu Dhabi, is a ...

Dementia is a condition that affects memory, thinking, and behavior, and it tends to get worse over time. While there is ...

Andrew Frank and Katherine C. Pearson, QUOI MediaAlzheimer’s disease is an insidious and relentless loss of memory and thinking, accompanied by a gradual ...

.

A promising new study from the Knight Family DIAN-TU research group at Washington University School of Medicine has found that starting Alzheimer’s treatment years before symptoms begin could delay — ...